Price
CHART BY
Frequently asked questions
What is Harrow Health's market capitalization?
The market capitalization of Harrow Health is $1.27B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for Harrow Health?
Harrow Health's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$1.00. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Harrow Health's stock?
Currently, 9 analysts cover Harrow Health's stock, with a consensus target price of $65.00. Analyst ratings provide insights into the stock's expected performance.
What is Harrow Health's revenue over the trailing twelve months?
Over the trailing twelve months, Harrow Health reported a revenue of $275.59M.
What is the EBITDA for Harrow Health?
Harrow Health's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is $26.95M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Harrow Health?
Harrow Health has a free cash flow of $5.02M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Harrow Health have, and what sector and industry does it belong to?
Harrow Health employs approximately 373 people. It operates in the Health Care sector, specifically within the Major Pharmaceuticals industry.
What is the free float of Harrow Health's shares?
The free float of Harrow Health is 31.80M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $1.27B
- EPS (TTM)
- -$1.00
- Free Float
- 31.80M
- Revenue (TTM)
- $275.59M
- EBITDA (TTM)
- $26.95M
- Free Cashflow (TTM)
- $5.02M
Pricing
- 52W span
- $28.55$54.81
Analyst Ratings
The price target is $65.00 and the stock is covered by 9 analysts.
Buy
9
Hold
0
Sell
0
Information
Harrow, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Branded and ImprimisRx. The Branded segment includes activities of the company’s FDA approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain branded products. The ImprimisRx segment represents activities in the company’s ophthalmology-focused pharmaceutical compounding business. The company was founded by Mark L. Baum and Robert J. Kammer on January 11, 2006 and is headquartered in Nashville, TN.
- Employees
- 373
- Industries
- Major Pharmaceuticals
- Sector
- Health Care
Identifier
- Primary Ticker
- HROW
Fundamentals & EOD data from FactSet